(-)-(3R)-3-Aminohexanol | 64197-81-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (-)-(3R)-3-Aminohexanol
• 英文别名: (R)-3-Aminohexan-1-ol；(3R)-3-aminohexan-1-ol
• CAS: 64197-81-5
• 化学式: C₆H₁₅NO
• 分子量: 117.191
• InChiKey: YZOKDOZIDBMHOK-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (-)-(3R)-3-Aminohexanol 在 ruthenium trichloride 、 sodium periodate 、 碳酸氢钠 作用下， 以 四氯化碳 、 水 、 乙酸乙酯 、 乙腈 为溶剂， 反应 1.0h， 生成 (R)-3-tert-Butoxycarbonylaminohexanoic acid
  参考文献：
  名称：

  纯手性β-氨基酸的新方法

  摘要：

  描述了从N -Cbz-L-高丝氨酸内酯开始，通过形成保留了原始α-碳手性的α-氨基芳基，烯基或炔基酮，有效合成γ-芳基或烷基取代的β-氨基酸的方法。

  DOI：

  10.1016/0040-4039(96)00518-7
• 作为产物：
  描述：

  (S)-4-(2-Hydroxy-ethyl)-5-vinyl-oxazolidin-2-one 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、101.32 kPa 条件下， 反应 4.0h， 生成 (-)-(3R)-3-Aminohexanol
  参考文献：
  名称：

  纯手性β-氨基酸的新方法

  摘要：

  描述了从N -Cbz-L-高丝氨酸内酯开始，通过形成保留了原始α-碳手性的α-氨基芳基，烯基或炔基酮，有效合成γ-芳基或烷基取代的β-氨基酸的方法。

  DOI：

  10.1016/0040-4039(96)00518-7

文献信息

• CONSTRUCTION AND SCREENING OF SOLUTION-PHASE DERIVED LIBRARY OF FENBUFEN AND ETHACRYNIC ACID
  申请人：Yu Chung-Shan

  公开号：US20110306668A1

  公开（公告）日：2011-12-15

  A process for synthesizing and screening solution phase derived libraries of fenbufen and ethacrynic acid is provided in the present invention. Compounds in the present invention having cytotoxicities are useful for a variety of therapeutic applications.

  本发明提供了一种合成和筛选溶液相衍生的芬布芬和依他克酸库的过程。本发明中具有细胞毒性的化合物对多种治疗应用是有用的。
• N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
  申请人：PIMCO 2664 LIMITED

  公开号：US10029979B2

  公开（公告）日：2018-07-24

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumor cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

  本发明一般涉及治疗化合物领域。更具体地说，本发明涉及某些取代的 N-(4-羟基-4-甲基-环己基)-4-苯基苯磺酰胺和 N-(4-羟基-4-甲基-环己基)-4-(2-吡啶基)苯磺酰胺化合物（在此统称为 HMC 化合物），这些化合物可用于治疗各种疾病（例如疾病），包括炎症和/或关节破坏和/或骨质流失；免疫系统过度和/或不适当和/或长期激活引起的疾病；炎症和自身免疫性疾病，例如类风湿性关节炎；银屑病；银屑病关节炎；慢性阻塞性肺疾病（COPD）；哮喘；动脉粥样硬化；炎症性肠病；强直性脊柱炎；多发性硬化症；系统性红斑狼疮；斯约格伦综合征；与骨质流失有关的疾病，如类风湿性关节炎、骨质疏松症、癌症相关骨病或帕吉特氏病中与破骨细胞过度活动有关的骨质流失；癌症，如血液恶性肿瘤，如多发性骨髓瘤、白血病或淋巴瘤，或实体瘤癌症，如膀胱癌、乳腺癌（女性和/或男性）、结肠癌、肾细胞癌、肾癌、肺癌、胰腺癌、胃癌、前列腺癌、脑癌、皮肤癌、甲状腺癌、基底细胞母细胞瘤或黑色素瘤；与纤维化相关的疾病，如系统性硬化症或硬皮病；或罕见的血管性疾病，如白塞氏病。本发明还涉及包含此类化合物的药物组合物，以及此类化合物和组合物在治疗等方面的用途。
• Habermehl,G.; Andres,H., Justus Liebigs Annalen der Chemie, 1977, p. 800 - 805
  作者：Habermehl,G.、Andres,H.

  DOI：——

  日期：——
• N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE
  申请人：PIMCO 2664 LIMITED

  公开号：US20170217881A1

  公开（公告）日：2017-08-03

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.
• US9796670B2
  申请人：——

  公开号：US9796670B2

  公开（公告）日：2017-10-24